🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06504446
Active, not recruiting Phase 2

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446 · tracked via the Priya Life Science UK tracker
Sponsor
Nocion Therapeutics
Phase
Phase 2
Started
2024-09-24
Last updated
2026-06-11

Condition(s) studied

Refractory or Unexplained Chronic Cough

Investigational drug(s) / intervention(s)

NOC-110Placebo

NOC-110: Inhalation powder

Placebo: Inhalation powder

Study summary

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Refractory or unexplained chronic cough for ≥ 12 months. * Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study. * Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol. * Able to provide Informed Consent. Exclusion Criteria: * Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds. * Participants who are currently participating in another drug or device clinical study * Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening. * Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease. * Respiratory tract infection within 4 weeks of Screening or during screening period. * Any female who is pregnant or lactating or wishing to become pregnant. * Donation of \> 1 Unit (450 milliliter or more) of blood within 60 days prior to the first dosing. * Alcohol or drug use disorder within the past 2 years. * Current smoker/vaper or individuals who have given up smoking within the past 6 months of screening, and/or those with \>20 pack-year smoking history. * Current opiate/opioid use or medical history of opiate/opioid use disorder. * History of concurrent malignancy or recurrence of malignancy in the last 2 years. * Body Mass Index of ≥40 kg/m2. * Positive results for human immunodeficiency virus, hepatitis B, or hepatitis C virus. * Unable to refrain from the use of medications and treatments that can impact cough during the study. * Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).

Primary outcome measure(s)

Trial sites (106)

FacilityCityRegionStatus
G & L Research, LLC Foley Alabama
Medical Research of Arizona Scottsdale Arizona
AMR Phoenix Tempe Arizona
Little Rock Allergy & Asthma, P.A. Clinical Research Center Little Rock Arkansas
So Cal Clinical Research Huntington Beach California
Allergy and Asthma Associates of Southern California dba Southern California Research Laguna Niguel California
Paradigm Clinical Research Centers, LLC - Modesto Modesto California
NewportNativeMD,Inc Newport Beach California
Center for Clinical Trials, LLC Paramount California
Paradigm Clinical Research Centers, LLC Redding California
DaVinci Research LLC. Roseville California
Allergy & Asthma Associates of Santa Clara Valley San Jose California
California Allergy & Asthma Medical Group Inc. San Jose California
Allergy, Asthma, and Immunology Medical Group Ventura California
Allergy and Asthma Clinical Research Inc Walnut Creek California
Lynn Institute of Denver Aurora Colorado
Innovative Research of West Florida, Inc. Clearwater Florida
Omega Research Debary, LLC DeBary Florida
Jacksonville Center for Clinical Research Jacksonville Florida
Clinical Site Partners, LLC Leesburg dba Flourish Research Leesburg Florida
Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research Miami Florida
Well Pharma Medical Research Corporation Miami Florida
University of South Florida - PARENT Tampa Florida
Clinical Site Partners, LLC Orlando dba Flourish Research Winter Park Florida
Aeroallergy Research Laboratories of Savannah, Inc. Savannah Georgia
Duly Health and Care Winfield Illinois
Accellacare of McFarland Clinic Ames Iowa
The Iowa Clinic, PC West Des Moines Iowa
University of Kansas Medical Center Kansas City Kansas
Bluegrass Allergy Research Lexington Kentucky
Allergy & Asthma Specialists, PSC Owensboro Kentucky
Continental Clinical Solutions, LLC Towson Maryland
Infinity Medical Research Inc Russells Mills Massachusetts
Clinical Research Institute Minneapolis Minnesota
Mayo Clinic - Rochester Rochester Minnesota
The Curators of the University of Missouri on behalf of University of Missouri Health Care Columbia Missouri
Midwest Chest Consultants Saint Charles Missouri
Sundance Clinical Research St Louis Missouri
The Clinical Research Center, LLC St Louis Missouri
Montana Medical Research, Inc. Missoula Montana

+ 66 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06504446 on ClinicalTrials.gov ↗ ← All trials in the UK